Trifecta主动脉心包瓣膜多中心中期临床与血流动力学结果
多中心前瞻性非随机随访研究纳入710例植入Trifecta主动脉心包瓣膜患者,平均年龄72.4±9.3岁,男性66.3%。术后6年平均跨瓣压差11.0 mmHg,有效瓣口面积指数0.80 cm²/m²,无中重度返流比例95.2%,瓣膜相关死亡率、非结构功能障碍及瓣周漏免除率分别为98.3%、98.6%、98.9%,因结构瓣膜衰败再手术免除率97.3%。结论认为该瓣膜安全有效,血流动力学和耐久性良好。
要点
- 术后6年平均跨瓣压差11.0 mmHg,有效瓣口面积指数0.80 cm²/m²。
- 6年无中重度瓣膜返流比例为95.2%(80/84)。
- 6年瓣膜相关死亡率免除率98.3%,再手术免除率97.3%。
核心结论
- Trifecta主动脉心包瓣膜在6年随访中表现出良好的血流动力学性能和耐久性,是安全有效的瓣膜替代物。
研究设计与样本
- 多中心、前瞻性、非随机随访研究,纳入710例接受外科植入Trifecta主动脉心包瓣膜的患者,每年随访至6年。
主要发现
- 术后6年平均跨瓣压差11.0 mmHg,平均有效瓣口面积指数0.80 cm²/m²。
- 6年无中重度瓣膜返流比例为95.2%(80/84)。
- 6年瓣膜相关死亡率免除率98.3%,非结构功能障碍免除率98.6%,瓣周漏免除率98.9%。
- 6年因结构瓣膜衰败再手术免除率97.3%(95%置信限98.6-94.7)。
- 术前50.8%患者为NYHA III或IV级,术后6年95.8%(92/96)为NYHA I或II级。
临床怎么用
- 对于需行主动脉瓣置换的患者,Trifecta瓣膜可作为安全有效的生物瓣选择,中期血流动力学和耐久性良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the midterm hemodynamic performance and clinical outcomes of the Trifecta aortic pericardial valve. METHODS: In a multicenter, prospective, nonrandomized, follow-up study, 710 patients underwent surgical implantation of a pericardial stented aortic prosthesis (Trifecta valve; St Jude Medical, St. Paul, Minn). The valve is constructed from bovine pericardium mounted externally onto a titanium stent. Subjects were followed on an annual basis over 6 years. RESULTS: Operations were performed from 2007 to 2009, and mean age was 72.4 ± 9.3 years; 471 of 710 (66.3%) were men. Preoperatively, 361 of 710 (50.8%) of patients were in New York Heart Association class III or IV, and at 6 years postoperatively, 92 of 96 (95.8%) were New York Heart Association class I or II. Six years postoperatively, average mean gradient across all valve sizes was 11.0 mm Hg, and the average effective orifice area index was 0.80 cm2/m2. The proportion of patients without moderate-to-severe valvular regurgitation at 6 years was 95.2% (80/84). Six years postoperatively, freedom from valve-related mortality, nonstructural dysfunction, and paravalvular leak were 98.3%, 98.6%, and 98.9%, respectively, and freedom from reoperation due to structural valve deterioration was 97.3% (95% confidence limits, 98.6-94.7). CONCLUSION: These midterm results demonstrate that the Trifecta valve is a safe and effective valve substitute with excellent hemodynamic performance and durability that is maintained through the 6-year follow-up period.
引用
- Goldman S, Cheung A, Bavaria JE, et al. Midterm, multicenter clinical and hemodynamic results for the Trifecta aortic pericardial valve. J Thorac Cardiovasc Surg. 2016. PMID: 27964975. doi:10.1016/j.jtcvs.2016.09.089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。